Profund Advisors LLC Sells 1,777 Shares of FibroGen Inc (NASDAQ:FGEN)

Profund Advisors LLC reduced its position in FibroGen Inc (NASDAQ:FGEN) by 8.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,484 shares of the biopharmaceutical company’s stock after selling 1,777 shares during the period. Profund Advisors LLC’s holdings in FibroGen were worth $925,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Manchester Capital Management LLC bought a new stake in shares of FibroGen in the 1st quarter valued at about $39,000. Cornerstone Advisors Inc. boosted its stake in FibroGen by 672.8% in the 1st quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 693 shares in the last quarter. Captrust Financial Advisors acquired a new stake in FibroGen in the 2nd quarter worth approximately $90,000. AlphaCrest Capital Management LLC acquired a new stake in FibroGen in the 1st quarter worth approximately $283,000. Finally, Commonwealth Equity Services LLC acquired a new stake in FibroGen in the 2nd quarter worth approximately $295,000. Institutional investors and hedge funds own 69.57% of the company’s stock.

FGEN stock traded up $0.04 during trading on Monday, reaching $41.53. The company had a trading volume of 129,137 shares, compared to its average volume of 505,731. The firm has a 50-day simple moving average of $44.70 and a 200-day simple moving average of $46.23. The company has a market cap of $3.61 billion, a price-to-earnings ratio of -40.32 and a beta of 1.87. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.73. FibroGen Inc has a twelve month low of $33.51 and a twelve month high of $61.95.

FibroGen (NASDAQ:FGEN) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $1.75. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The company had revenue of $191.57 million during the quarter, compared to analysts’ expectations of $29.03 million. During the same period last year, the business earned ($0.28) EPS. FibroGen’s revenue for the quarter was up 335.9% on a year-over-year basis. Sell-side analysts expect that FibroGen Inc will post -0.37 earnings per share for the current year.

In other FibroGen news, SVP Elias Kouchakji sold 2,873 shares of FibroGen stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $45.00, for a total transaction of $129,285.00. Following the completion of the sale, the senior vice president now directly owns 109,199 shares in the company, valued at approximately $4,913,955. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $40.95, for a total transaction of $245,700.00. Following the sale, the director now owns 34,400 shares of the company’s stock, valued at $1,408,680. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 234,768 shares of company stock valued at $10,511,022. Company insiders own 7.83% of the company’s stock.

A number of research firms recently commented on FGEN. Mizuho reiterated a “buy” rating and issued a $65.00 target price on shares of FibroGen in a research note on Monday, August 26th. ValuEngine upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th. William Blair reiterated a “hold” rating on shares of FibroGen in a research note on Tuesday, July 2nd. TheStreet upgraded shares of FibroGen from a “d+” rating to a “c” rating in a research note on Tuesday, August 13th. Finally, Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $51.00 target price for the company in a research note on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. FibroGen has a consensus rating of “Buy” and a consensus price target of $61.00.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also: What does a neutral rating on stocks mean?

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.